Literature DB >> 29181185

Prognostic factors in patients with skeletal-related events at non-small-cell lung cancer diagnosis.

Hiroyuki Tominaga1, Takao Setoguchi2, Hirofumi Shimada1, Satoshi Nagano1, Hiromi Sasaki1, Yasuhiro Ishidou3, Masami Sato4, Keiko Mizuno5, Hiromasa Inoue5, Setsuro Komiya1.   

Abstract

The aim of the present study was to detect prognostic factors in patients with skeletal-related events (SREs) and bone metastasis at the time of non-small-cell lung cancer (NSCLC) diagnosis. A total of 85 NSCLC patients were retrospectively enrolled, 47 (55.2%) of whom presented with SREs at the time of NSCLC diagnosis. Multivariate logistic regression analysis identified squamous cell carcinoma as a risk factor for SRE. Kaplan-Meier analysis demonstrated that there was no difference in the overall survival between the SRE and no SRE groups. Cox hazard model revealed that a higher Eastern Cooperative Oncology Group (ECOG) performance status (PS) score was a risk factor for poor prognosis, while surgery for bone metastasis and molecular-targeted therapy were factors for better prognosis in patients with SREs at the time of NSCLC diagnosis. Multivariate analysis revealed that a higher ECOG PS score and metastasis to the adrenal gland were risk factors for poor prognosis, while surgery for bone metastasis and molecular-targeted therapy were factors for better prognosis. Thus, while surgical treatment and molecular-targeted therapy appear to improve the prognosis of patients with bone metastasis at the time of NSCLC diagnosis, those with a higher ECOG PS score and adrenal metastasis may benefit more from radiotherapy or supportive care.

Entities:  

Keywords:  bone metastases; molecular-targeted treatment; non-small-cell lung cancer; prognostic factors; skeletal-related events

Year:  2017        PMID: 29181185      PMCID: PMC5700282          DOI: 10.3892/mco.2017.1394

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  30 in total

1.  Clinical utility of the pretreatment glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer.

Authors:  Elaine Y L Leung; Hazel R Scott; Donald C McMillan
Journal:  J Thorac Oncol       Date:  2012-04       Impact factor: 15.609

2.  Factors associated with long-term survival of patients with advanced non-small cell lung cancer.

Authors:  Etienne Giroux Leprieur; Armelle Lavole; Anne-Marie Ruppert; Valérie Gounant; Marie Wislez; Jacques Cadranel; Bernard Milleron
Journal:  Respirology       Date:  2012-01       Impact factor: 6.424

3.  Prognostic factors in patients with advanced non-small cell lung cancer: data from the phase III FLEX study.

Authors:  R Pirker; J R Pereira; A Szczesna; J von Pawel; M Krzakowski; R Ramlau; I Vynnychenko; K Park; W E E Eberhardt; F de Marinis; S Heeger; T Goddemeier; K J O'Byrne; U Gatzemeier
Journal:  Lung Cancer       Date:  2012-04-11       Impact factor: 5.705

4.  Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis.

Authors:  Hyun-Mi Bae; Se-Hoon Lee; Tae Min Kim; Dong-Wan Kim; Seok-Chul Yang; Hong Gyun Wu; Young Whan Kim; Dae Seog Heo
Journal:  Lung Cancer       Date:  2012-06-04       Impact factor: 5.705

5.  Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial.

Authors:  Lee S Rosen; David Gordon; N Simon Tchekmedyian; Ronald Yanagihara; Vera Hirsh; Maciej Krzakowski; Marek Pawlicki; Paul De Souza; Ming Zheng; Gladys Urbanowitz; Dirk Reitsma; John Seaman
Journal:  Cancer       Date:  2004-06-15       Impact factor: 6.860

6.  Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status.

Authors:  Aristea Kalikaki; Anastasios Koutsopoulos; Dora Hatzidaki; Maria Trypaki; Emmanouel Kontopodis; Efstathios Stathopoulos; Dimitris Mavroudis; Vassilis Georgoulias; Alexandra Voutsina
Journal:  Lung Cancer       Date:  2009-10-24       Impact factor: 5.705

7.  Human breast adenocarcinoma (MDA-231) and human lung squamous cell carcinoma (Hara) do not have the ability to cause bone resorption by themselves during the establishment of bone metastasis.

Authors:  Amy Tomita; Tatsuhiko Kasaoka; Takashi Inui; Minako Toyoshima; Hiroko Nishiyama; Hiromasa Saiki; Haruo Iguchi; Motowo Nakajima
Journal:  Clin Exp Metastasis       Date:  2008-02-27       Impact factor: 5.150

8.  Distribution and prognosis of uncommon metastases from non-small cell lung cancer.

Authors:  Fei-Yu Niu; Qing Zhou; Jin-Ji Yang; Wen-Zhao Zhong; Zhi-Hong Chen; Wei Deng; Yan-Yan He; Hua-Jun Chen; Zhu Zeng; E-E Ke; Ning Zhao; Na Zhang; Hui-Wen Sun; Qiu-Yi Zhang; Zhi Xie; Xu-Chao Zhang; Yi-Long Wu
Journal:  BMC Cancer       Date:  2016-02-24       Impact factor: 4.430

9.  Natural History of Non-Small-Cell Lung Cancer with Bone Metastases.

Authors:  Daniele Santini; Santini Daniele; Sandro Barni; Barni Sandro; Salvatore Intagliata; Intagliata Salvatore; Alfredo Falcone; Falcone Alfredo; Francesco Ferraù; Ferraù Francesco; Domenico Galetta; Galetta Domenico; Luca Moscetti; Moscetti Luca; Nicla La Verde; La Verde Nicla; Toni Ibrahim; Ibrahim Toni; Fausto Petrelli; Petrelli Fausto; Enrico Vasile; Vasile Enrico; Laura Ginocchi; Ginocchi Laura; Davide Ottaviani; Ottaviani Davide; Flavia Longo; Longo Flavia; Cinzia Ortega; Ortega Cinzia; Antonio Russo; Russo Antonio; Giuseppe Badalamenti; Badalamenti Giuseppe; Elena Collovà; Collovà Elena; Gaetano Lanzetta; Lanzetta Gaetano; Giovanni Mansueto; Mansueto Giovanni; Vincenzo Adamo; Adamo Vincenzo; Filippo De Marinis; De Marinis Filippo; Maria Antonietta Satolli; Flavia Cantile; Cantile Flavia; Andrea Mancuso; Mancuso Andrea; Francesca Maria Tanca; Raffaele Addeo; Addeo Raffaele; Marco Russano; Russano Marco; Michelle Sterpi; M Sterpi; Francesco Pantano; Pantano Francesco; Bruno Vincenzi; Vincenzi Bruno; Giuseppe Tonini; Tonini Giuseppe
Journal:  Sci Rep       Date:  2015-12-22       Impact factor: 4.379

10.  Prediction of survival prognosis after surgery in patients with symptomatic metastatic spinal cord compression from non-small cell lung cancer.

Authors:  Mingxing Lei; Yaosheng Liu; Chuanghao Tang; Shaoxing Yang; Shubin Liu; Shiguo Zhou
Journal:  BMC Cancer       Date:  2015-11-05       Impact factor: 4.430

View more
  4 in total

1.  Clinical outcome for small cell lung cancer patients with bone metastases at the time of diagnosis.

Authors:  Linlin Gong; Liming Xu; Zhiyong Yuan; Zhongqiu Wang; Lujun Zhao; Ping Wang
Journal:  J Bone Oncol       Date:  2019-11-02       Impact factor: 4.072

2.  Development and validation of a nomogram in survival prediction among advanced breast cancer patients.

Authors:  Jianli Zhao; Yaping Yang; Danmei Pang; Yunfang Yu; Xiao Lin; Kai Chen; Guolin Ye; Jun Tang; Qian Hu; Jie Chai; Zhuofei Bi; Linxiaoxiao Ding; Wenjing Wu; Yinduo Zeng; Xiujuan Gui; Donggeng Liu; Herui Yao; Ying Wang
Journal:  Ann Transl Med       Date:  2020-11

3.  PLOD2-driven IL-6/STAT3 signaling promotes the invasion and metastasis of oral squamous cell carcinoma via activation of integrin β1.

Authors:  Ken Saito; Ayaka Mitsui; I Wayan Sumardika; Yusuke Yokoyama; Masakiyo Sakaguchi; Eisaku Kondo
Journal:  Int J Oncol       Date:  2021-04-23       Impact factor: 5.650

4.  Osimertinib regressed an EGFR-mutant lung-adenocarcinoma bone-metastasis mouse model and increased long-term survival.

Authors:  Takashi Higuchi; Norihiko Sugisawa; Jun Ho Park; Yu Sun; Guangwei Zhu; Norio Yamamoto; Katsuhiro Hayashi; Hiroaki Kimura; Shinji Miwa; Kentaro Igarashi; Michael Bouvet; Shree Ram Singh; Hiroyuki Tsuchiya; Robert M Hoffman
Journal:  Transl Oncol       Date:  2020-07-10       Impact factor: 4.243

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.